
Jade Biosciences, Inc.: shareholders and insiders
Price
$15.31
November 20, 2026Market cap $1.1B
What Ploutos Investor adds for Jade Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by Jade Biosciences's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Fairmount Funds Management LLCwith 4 more personsShare of class20.0%
- FMRwith 1 more personShare of class14.7%
- JANUS HENDERSON GROUP Ltd.Share of class10.6%
- Venrock Healthcare Capital Partners III, L.P.with 6 more personsShare of class8.30%
- RA Capital Management, L.P.with 3 more personsShare of class7.00%
- Franklin Templeton, Inc.with 2 more personsShare of class6.00%
- BlackRock, Inc.Share of class5.20%
- Paradigm BioCapital Advisors LPwith 3 more personsShare of class5.10%
- Bellevue Group AGwith 1 more personShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLCwith 4 more persons | 20.0% | 14.07M | Jun 9, 20263 filings since May 1, 2025 | 13D/A | |
| FMRwith 1 more person | 14.7% | 4.74M | Jun 6, 2025 | 13G | |
| JANUS HENDERSON GROUP Ltd. | 10.6% | 6.27M | Jul 8, 20263 filings since Feb 17, 2026 | 13G/A | |
| Venrock Healthcare Capital Partners III, L.P.with 6 more persons | 8.30% | 5.15M | Aug 14, 20263 filings since May 5, 2025 | 13G/A | |
| RA Capital Management, L.P.with 3 more persons | 7.00% | 3.21M | Oct 16, 20252 filings since Apr 30, 2025 | 13G | |
| Franklin Templeton, Inc.with 2 more persons | 6.00% | 3.81M | Oct 28, 2026 | 13G | |
| BlackRock, Inc. | 5.20% | 3.32M | Oct 27, 20264 filings since Jul 17, 2025 | 13G | |
| Paradigm BioCapital Advisors LPwith 3 more persons | 5.10% | 3.11M | Jul 17, 2026 | 13G | |
| Bellevue Group AGwith 1 more person | 5.00% | 3.06M | Aug 14, 20262 filings since Feb 17, 2026 | 13G/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Fairmount Funds Management LLC20.0%From the filing of Oct 8, 2025
Item 4 of the Statement is hereby amended and supplemented as follows: Subscription Agreement On October 6, 2025, the Company entered into a securities purchase agreement (the "Subscription Agreement") for a private investment in public equity ("PIPE") with certain institutional and accredited investors, including Fund II. The PIPE closed on October 8, 2025. Pursuant to the terms of the Subscription Agreement, Fund II purchased a total of 1,333,126 shares of Common Stock at a purchase price of $9.14 per share and Pre-Funded Warrants to purchase 855,047 shares of Common Stock at a purchase price of $9.1399 per Pre-Funded Warrant, which represents the per share purchase price of the shares…
From the filing of Oct 8, 2025
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Sofinnova Venture Partners X, L.P. ("SVP X")13D0.30%Mar 5, 202613D/A
- Deep Track Capital, LP0.00%Feb 13, 202613G/A
- The Vanguard Group4.24%Jan 30, 202613G/A
- Frazier Life Sciences Public Fund, L.P.4.20%Nov 14, 202513G/A
- TCG Crossover GP I, LLC0.20%May 15, 202513G/A
- Atlas Venture Fund XII, L.P.13D0.20%Apr 30, 202513D/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter+129%
- Citadel Advisors (Griffin)In the quarter-0.0%
- Millennium Mgmt (Englander)In the quarter+34%
- D.E. ShawIn the quarter+132%
- Renaissance TechnologiesIn the quarter-71%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 382.5K | +129% | $5.4M | 0.01% |
| Citadel Advisors (Griffin) | 929.3K | -0.0% | $13M | 0.01% |
| Millennium Mgmt (Englander) | 420.5K | +34% | $5.9M | 0.00% |
| D.E. Shaw | 119.7K | +132% | $1.7M | 0.00% |
| Renaissance Technologies | 21.1K | -71% | $300.0K | 0.00% |
| AQR Capital | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.2% of its shares outstanding were held short, -7.5% since the report before.
- Shares held short
- 11.21M
- 16.2%
- Since the report before12.12M on Sep 30, 2026
- -7.5%
- 10.9
- 1.03M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 93%
- Report date
- Oct 15, 2026
- Shares held short
- Apr 30, 2025: Shares held short 148.0K
- May 15, 2025: Shares held short 162.9K
- May 30, 2025: Shares held short 238.4K
- Jun 13, 2025: Shares held short 379.5K
- Jun 30, 2025: Shares held short 2.03M
- Jul 15, 2025: Shares held short 1.87M
- Jul 31, 2025: Shares held short 1.82M
- Aug 15, 2025: Shares held short 1.90M
- Aug 29, 2025: Shares held short 1.81M
- Sep 15, 2025: Shares held short 1.74M
- Sep 30, 2025: Shares held short 1.76M
- Oct 15, 2025: Shares held short 1.71M
- Oct 31, 2025: Shares held short 1.03M
- Nov 14, 2025: Shares held short 1.07M
- Nov 28, 2025: Shares held short 1.17M
- Dec 15, 2025: Shares held short 1.05M
- Dec 31, 2025: Shares held short 1.55M
- Jan 15, 2026: Shares held short 1.35M
- Jan 30, 2026: Shares held short 1.45M
- Feb 13, 2026: Shares held short 1.56M
- Feb 27, 2026: Shares held short 1.56M
- Mar 13, 2026: Shares held short 1.53M
- Mar 31, 2026: Shares held short 1.25M
- Apr 15, 2026: Shares held short 3.06M
- Apr 30, 2026: Shares held short 3.10M
- May 15, 2026: Shares held short 3.40M
- May 29, 2026: Shares held short 3.16M
- Jun 15, 2026: Shares held short 4.95M
- Jun 30, 2026: Shares held short 8.15M
- Jul 15, 2026: Shares held short 7.53M
- Jul 31, 2026: Shares held short 8.69M
- Aug 14, 2026: Shares held short 9.65M
- Aug 31, 2026: Shares held short 9.99M
- Sep 15, 2026: Shares held short 10.98M
- Sep 30, 2026: Shares held short 12.12M
- Oct 15, 2026: Shares held short 11.21M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading51.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 51.3% of the shares in the reported trades were short sales, against 63.0% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 51.3%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 63.0%
- Change
- -11.7 pts
- Short sales a dayon average, of 448.7K shares
- 230.1K
- More than atof 3,666 US-listed companies, same days
- 53%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 53.5%
- Oct 15, 2026: Short sales 66.1%
- Oct 16, 2026: Short sales 74.1%
- Oct 19, 2026: Short sales 79.2%
- Oct 20, 2026: Short sales 73.5%
- Oct 21, 2026: Short sales 80.7%
- Oct 22, 2026: Short sales 65.2%
- Oct 23, 2026: Short sales 65.7%
- Oct 26, 2026: Short sales 87.2%
- Oct 27, 2026: Short sales 81.1%
- Oct 28, 2026: Short sales 35.4%
- Oct 29, 2026: Short sales 34.4%
- Oct 30, 2026: Short sales 51.8%
- Nov 2, 2026: Short sales 54.8%
- Nov 3, 2026: Short sales 35.6%
- Nov 4, 2026: Short sales 74.9%
- Nov 5, 2026: Short sales 76%
- Nov 6, 2026: Short sales 68.3%
- Nov 9, 2026: Short sales 50.1%
- Nov 10, 2026: Short sales 62.1%
- Nov 11, 2026: Short sales 55.3%
- Nov 12, 2026: Short sales 72.8%
- Nov 13, 2026: Short sales 67.3%
- Nov 16, 2026: Short sales 44.1%
- Nov 17, 2026: Short sales 18.9%
- Nov 18, 2026: Short sales 70%
- Nov 19, 2026: Short sales 66.1%
- Nov 20, 2026: Short sales 80.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Rajeev M. ShahDirector,TenPercentOwnerDirectly–
- David S. GrayzelDirectorDirectly–
- Tom FrohlichChief Executive OfficerDirectly6,000
- Hunter GilliesCHIEF MEDICAL OFFICERDirectly5,602
- George A EldridgeSEE REMARKSDirectly5,022
- Ralph NivenCHIEF SCIENTIFIC OFFICERDirectly1,609
- Benjamin T DakeSEE REMARKSDirectly1,359
- Timothy P NoyesCHIEF EXECUTIVE OFFICERDirectly1,293
- Marinus VerwijsCHIEF TECHNICAL OFFICERDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Rajeev M. ShahDirector,TenPercentOwner | – | 7.89M | Jun 17, 2024 | Form 4 |
| David S. GrayzelDirector | – | 14.5K | Apr 9, 2024 | Form 4 |
| Tom FrohlichChief Executive Officer | 6,000 | – | May 16, 2025 | Form 4 |
| Hunter GilliesCHIEF MEDICAL OFFICER | 5,602 | – | Jun 13, 2024 | Form 4 |
| George A EldridgeSEE REMARKS | 5,022 | – | Jun 14, 2024 | Form 4 |
| Ralph NivenCHIEF SCIENTIFIC OFFICER | 1,609 | – | Feb 5, 2024 | Form 4 |
| Benjamin T DakeSEE REMARKS | 1,359 | – | Apr 17, 2024 | Form 4 |
| Timothy P NoyesCHIEF EXECUTIVE OFFICER | 1,293 | – | May 16, 2024 | Form 4 |
| Marinus VerwijsCHIEF TECHNICAL OFFICER | – | – | Jun 14, 2024 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.32%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.21%
- IWCiShares Micro-Cap ETFWeight in the fund0.16%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.04%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.01%
- ITOTiShares Core S&P Total U.S. Stock Market ETFWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
8 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 78
- Q4 2025: Managers 105
- Q1 2026: Managers 120
- Q2 2026: Managers 154
Institutional investors by quarter
The fund managers holding JBIO, quarter by quarter, from Q2 2025 to Q2 2025, 1 more quarter
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 quarters.
Q2 2026: 154 managers held 72.90M shares, worth $1.6B. During the quarter 50 opened a position, 18 closed one, 57 added and 26 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+29%
- Jupiter TopcoIn the quarter
- Fairmount Funds ManagementIn the quarter
- Ra Capital ManagementIn the quarter
- Venrock AdviserIn the quarter
- Bellevue GroupIn the quarter-13%
- Paradigm Biocapital AdvisorsIn the quarter
- BlackRockIn the quarter+21%
- Franklin ResourcesIn the quarter
- State StreetIn the quarter+256%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 9.13M | +29% | $203M |
| Jupiter Topco | 6.27M | $139M | |
| Fairmount Funds Management | 4.55M | $101M | |
| Ra Capital Management | 3.67M | $82M | |
| Venrock Adviser | 3.22M | $72M | |
| Bellevue Group | 3.06M | -13% | $68M |
| Paradigm Biocapital Advisors | 2.86M | $63M | |
| BlackRock | 2.80M | +21% | $62M |
| Franklin Resources | 2.79M | $62M | |
| State Street | 2.34M | +256% | $52M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Jade Biosciences's filings show?
Who buys and sells is one part of Jade Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have JBIO's insiders bought or sold?
From Jun 11, 2026 to Jun 26, 2026 Jade Biosciences's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold JBIO?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $13M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.